IPP Bureau
Wockhardt announces successful completion of pivotal Phase 3 pneumonia study of its macrolide antibiotic Nafithromycin WCK 4873
By IPP Bureau - December 12, 2023
The findings of Phase 3 study are in line with Phase 2 study conducted in the US and Europe
Briefs: GlaxoSmithKline Pharmaceuticals and Dr. Reddy's Laboratories
By IPP Bureau - December 10, 2023
Dr. Reddy's Laboratories has been issued a Form 483 with three observations
Pfizer presents marstacimab Phase 3 Data at ASH 2023
By IPP Bureau - December 10, 2023
Demonstrate significant bleed reduction in hemophilia A and B
Aptar Pharms opens new production facility at Taloja, Mumbai
By IPP Bureau - December 10, 2023
New facility is part of Aptar Pharma’s global expansion program
Astellas receives USFDA approval for expanded use of Cresemba for treatment of mucormycosis
By IPP Bureau - December 10, 2023
Cresemba is the only azole antifungal therapy approved for pediatric patients as young as one affected by these serious, potentially life-threatening infections
ExeGi Pharma announces first patient enrollment in the PROF Trial of EXE-346
By IPP Bureau - December 10, 2023
First published clinical trial using live biotherapeutic candidate in Covid-19 patients suggests role in improving outcomes
Max Healthcare acquires 550 bedded Sahara Hospital, Lucknow
By IPP Bureau - December 09, 2023
This acquisition marks Max Healthcare's entry into Lucknow
Fire accident at Parmax Pharma’s plant
By IPP Bureau - December 09, 2023
There has been no loss or injury to human life
European Commission approves Pfizer’s Elrexfio for multiple myeloma
By IPP Bureau - December 09, 2023
Conditional marketing authorization is based on clinically meaningful response rates, duration of response, and safety from the Phase 2 MagnetisMM-3 trial
Vertex and CRISPR Therapeutics announce USFDA approval of Casgevy for treatment of sickle cell disease
By IPP Bureau - December 09, 2023
Approximately 16,000 patients 12 years of age and older with severe sickle cell disease may now be eligible for this one-time treatment
Zepbound is now available in US for adults living with obesity
By IPP Bureau - December 09, 2023
Express Scripts to add Zepbound to National Preferred Formulary
Operations disrupted at NATCO Pharma's Manali, Chennai factory
By IPP Bureau - December 08, 2023
NATCO temporarily shut down the operations due to cyclone with flooding/water logging of the factory premises
TTK Healthcare halts operation at ortho implants plant at Ambattur
By IPP Bureau - December 08, 2023
The company is assessing the situation and simultaneously undertaking all the requisite action
Sarclisa Phase 3 trial met primary endpoint of progression free survival with newly diagnosed multiple myeloma not eligible for transplant
By IPP Bureau - December 08, 2023
Sarclisa added to bortezomib, lenalidomide and dexamethasone (VRd) significantly reduced the risk of disease progression or death compared with VRd alone
Novartis receives FDA approval for Fabhalta as the first oral monotherapy for adults with PNH
By IPP Bureau - December 08, 2023
Late-stage Fabhalta development program ongoing in multiple complement-mediated conditions
